Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 7/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SOD1 | P00441 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207914 | 0.84 | CHRNA7 (0.51) | CHRNA7KCNH2 | |
| SCHEMBL6403620 | 0.83 | CHRNA7 (0.48) | CHRNA7KCNH2 | |
| SCHEMBL6230975 | 0.82 | CHRNA7 (0.34) | CHRNA7KCNH2FLT1KDR | |
| SCHEMBL6207184 | 0.82 | FLT1 (0.39) | FLT1KDR | |
| SCHEMBL6398977 | 0.82 | KDR (0.34) | CHRNA7KCNH2FLT1KDR | |
| SCHEMBL6205699 | 0.82 | MAP2K1 (0.37) | CHRNA7KCNH2FLT1KDR | |
| SCHEMBL6207255 | 0.81 | CHRNA7 (0.33) | CHRNA7KCNH2FLT1KDR | |
| SCHEMBL6399621 | 0.80 | KDR (0.46) | QPCTFLT1KDR | |
| SCHEMBL6207867 | 0.80 | CHRNA7 (0.33) | CHRNA7KCNH2FLT1KDR | |
| SCHEMBL6399220 | 0.79 | CHRNA7 (0.43) | CHRNA7KCNH2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578736-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | claimed |
| WO-2004056789-A1 | MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | claimed |
| US-20050004186-A1 | MEK inhibiting compounds | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004186-A1 | MEK inhibiting compounds | MAPK1, MAP3K1, MAPK3 | QPCT 3018/4885CHRNA7 4667/4885KCNH2 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.